



ASX/Media Release

21 September 2015

ASX code: PIQ

Entitlement Issue Prospectus Despatch

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the **Company, PIQ**) is pleased to confirm the despatch today of the Company's Entitlement Issue Prospectus as lodged with ASIC and ASX on 11 September 2015, including the Entitlement and Acceptance Form.

The Entitlement Issue was proposed in the IPO prospectus as a "loyalty option" for those Shareholders who held their issued shares or new shareholders supporting the Company in its first few months after PIQ's admission to the Official List of ASX.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Media and Investor Inquiries
James Moses
Mandate Corporate
T: +61 420 991 574
E: james@mandatecorporate.com.au

Greg Wood
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems. It represents a massive global market estimated to be worth \$20.8 billion by 2018.

PILL is recognised as a global leader in its field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

- 1. Analytical services:** Specialist contract research, analytical testing and consultancy - fee for service model.
- 2. Diagnostics:** Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. The biomarkers market is estimated to double in size to \$45.6 billion by 2020.
- 3. Drug discovery:** Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth \$17 billion.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | F: +61 8 6151 1038 | E: enquiries@proteomicsinternational.com | W: proteomicsinternational.com

For personal use only